Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · August 26, 2020

Dual HER2 Blockade Plus an AI in Postmenopausal Women With HER2+/HR+ Metastatic Breast Cancer

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE
J. Clin. Oncol 2020 Aug 21;[EPub Ahead of Print], SRD Johnston, R Hegg, SA Im, IH Park, O Burdaeva, G Kurteva, MF Press, S Tjulandin, H Iwata, SD Simon, S Kenny, S Sarp, MA Izquierdo, LS Williams, WJ Gradishar

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading